查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1601707

吗啡药物市场 - 全球产业规模、份额、趋势、机会和预测，按产品、应用、地区和竞争细分，2019-2029F

Morphine Drugs Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 188 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年，全球吗啡药物市场估值为242.7 亿美元，预计在预测期内将稳定成长，到2029 年复合年增长率为4.71%。推动对有效疼痛管理解决方案的需求。吗啡是一种鸦片类镇痛药，以其有效的止痛特性而闻名，通常用于治疗中度至重度疼痛。该市场的成长受到多种因素的支撑，包括慢性疼痛发病率的上升、术后恢復和癌症相关疼痛。慢性疼痛是全球普遍存在的健康问题，对市场的扩张做出了重大贡献。关节炎、背痛和神经性疼痛等病症需要吗啡等强效止痛药才能充分缓解。癌症盛行率的不断上升，通常伴随着剧烈疼痛，刺激了对作为安宁疗护基石的吗啡药物的需求。术后恢復是吗啡药物市场的另一个关键驱动力。外科手术后，患者经常会经历不同程度的疼痛，吗啡具有治疗急性疼痛的功效，经常被用来提高术后舒适度。市场动态也受到药物配方和给药方法不断进步的影响。製药公司正在投资研发以优化吗啡配方，旨在提高生物利用度、最大限度地减少副作用并提高患者的依从性。然而，吗啡药物市场并非没有挑战。对阿片类药物滥用、成瘾以及潜在不良反应的担忧促使监管机构进行审查。在确保患者获得有效的疼痛缓解和解决阿片类药物相关问题之间取得微妙的平衡对于市场的可持续成长至关重要。从地理上看，市场格局是由医疗基础设施、疼痛管理实践和监管框架的地区差异决定的。由于成熟的医疗保健系统和对疼痛管理策略的更高认识，北美和欧洲是重要的市场。总之，全球吗啡药物市场的驱动力是对有效止痛药有效管理各种形式疼痛的迫切需求。随着世界各地的医疗保健系统努力应对疼痛管理的复杂性，吗啡药物市场仍然是为面临挑战性疼痛的患者提供缓解和提高生活品质的关键参与者。

市场概况
预测期 2025-2029
2023 年市场规模 242.7亿美元
2029 年市场规模 316.8亿美元
2024-2029 年复合年增长率 4.71%
成长最快的细分市场 缓解疼痛
最大的市场 北美洲

主要市场驱动因素

慢性疼痛的发生率上升

意识和可及性

主要市场挑战

副作用和耐受性

防滥用配方

主要市场趋势

日益关注个人化医疗

药物输送系统的进步

细分市场洞察

应用洞察

产品洞察

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：客户之声

第 5 章：全球吗啡药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 副产品（速释/短效鸦片类药物、缓释/长效鸦片类药物）
    • 按应用（止痛、麻醉、止咳、止腹泻、戒瘾）
    • 按公司划分 (2023)
    • 按地区
  • 市场地图

第 6 章：北美吗啡药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按申请
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 7 章：欧洲吗啡药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按申请
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 义大利
    • 西班牙

第 8 章：亚太地区吗啡药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按申请
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲

第 9 章：南美洲吗啡药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按申请
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲吗啡药物市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 按产品分类
    • 按申请
    • 按国家/地区
  • MEA：国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 埃及

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 併购（如有）
  • 产品发布（如有）
  • 最新动态

第 13 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi SA
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals

第 15 章：策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 23843

Global Morphine Drugs Market was valued at USD 24.27 billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 4.71% through 2029. The Global Morphine Drugs Market is a critical component of the pharmaceutical industry, driven by the widespread demand for effective pain management solutions. Morphine, an opioid analgesic, is renowned for its potent pain-relieving properties and is often prescribed for moderate to severe pain. The market's growth is underpinned by several factors, including the rising incidence of chronic pain conditions, post-surgical recovery, and cancer-related pain. Chronic pain, a pervasive health issue globally, contributes significantly to the market's expansion. Conditions such as arthritis, back pain, and neuropathic pain necessitate potent analgesics like morphine for adequate relief. The increasing prevalence of cancer, often accompanied by intense pain, fuels the demand for morphine drugs as a cornerstone in palliative care. Post-surgical recovery is another key driver of the morphine drugs market. Following surgical procedures, patients often experience varying degrees of pain, and morphine, with its efficacy in managing acute pain, is frequently prescribed to enhance postoperative comfort. The market's dynamics are also influenced by ongoing advancements in drug formulations and delivery methods. Pharmaceutical companies are investing in research and development to optimize morphine formulations, aiming to improve bioavailability, minimize side effects, and enhance patient compliance. However, the morphine drugs market is not without challenges. Concerns about opioid misuse, addiction, and the potential for adverse effects have prompted regulatory scrutiny. Striking a delicate balance between ensuring patient access to effective pain relief and addressing opioid-related concerns is crucial for the sustainable growth of the market. Geographically, the market's landscape is shaped by regional variations in healthcare infrastructure, pain management practices, and regulatory frameworks. North America and Europe are prominent markets due to established healthcare systems and higher awareness of pain management strategies. In conclusion, the Global Morphine Drugs Market is driven by the imperative need for potent analgesics to manage various forms of pain effectively. As healthcare systems worldwide grapple with the complexities of pain management, the market for morphine drugs remains a critical player in providing relief and improving the quality of life for patients facing challenging pain conditions.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 24.27 Billion
Market Size 2029USD 31.68 Billion
CAGR 2024-20294.71%
Fastest Growing SegmentPain Relief
Largest MarketNorth America

Key Market Drivers

Rising Incidence of Chronic Pain

The Global Morphine Drugs Market is significantly influenced by the rising incidence of chronic pain worldwide. Chronic pain, characterized by persistent discomfort lasting for an extended period, is a pervasive health concern affecting millions of individuals. Conditions such as arthritis, neuropathic pain, and musculoskeletal disorders contribute to the escalating prevalence of chronic pain. As populations age and chronic diseases become more widespread, the demand for effective pain management solutions, including potent analgesics like morphine, intensifies.

Chronic pain negatively impacts the quality of life, functional abilities, and mental well-being of affected individuals. The debilitating nature of chronic pain underscores the critical need for robust analgesic medications to provide relief and improve overall patient outcomes. Morphine, known for its efficacy in managing severe pain, emerges as a cornerstone in addressing the complexities of chronic pain conditions. The increasing burden of chronic pain is particularly notable in aging populations, where degenerative conditions and age-related ailments contribute to heightened pain experiences. Lifestyle factors, occupational stress, and sedentary habits further contribute to the prevalence of chronic pain across diverse demographic groups. Pharmaceutical companies and healthcare providers recognize the imperative to address the challenges posed by chronic pain, driving research and development efforts to enhance pain management strategies. Morphine drugs play a pivotal role in this landscape, offering a potent and established option for patients experiencing moderate to severe chronic pain. The rising incidence of chronic pain not only propels the demand for morphine drugs but also underscores the importance of comprehensive pain management approaches in global healthcare systems. Balancing effective pain relief with considerations for potential risks and side effects remains a key focus in optimizing the use of morphine and ensuring its continued relevance in addressing the complex landscape of chronic pain.

Awareness and Accessibility

Awareness and accessibility play pivotal roles in shaping the dynamics of the Global Morphine Drugs Market, influencing the adoption, prescription, and overall utilization of morphine for pain management. Increased awareness among healthcare professionals, patients, and the general public regarding the efficacy of morphine in addressing moderate to severe pain is crucial in driving its demand. Healthcare providers are key influencers in raising awareness about morphine as a potent analgesic. Continuous medical education programs and initiatives focused on pain management contribute to enhancing the understanding of morphine's role, benefits, and potential risks among healthcare professionals. This heightened awareness enables more informed prescribing practices and promotes responsible use. Patient awareness is equally essential in fostering acceptance and adherence to morphine therapy. Education campaigns that highlight the benefits, proper usage, and potential side effects of morphine contribute to destigmatizing opioid medications and addressing concerns about addiction. Empowering patients with accurate information ensures they actively participate in treatment decisions and follow prescribed regimens, optimizing the therapeutic outcomes of morphine. Accessibility to morphine is a critical determinant of its utilization, particularly in regions with varying healthcare infrastructure and regulatory frameworks. Ensuring that morphine is available and affordable in healthcare settings is vital for addressing pain effectively. Efforts to improve accessibility involve collaboration between healthcare providers, pharmaceutical manufacturers, and regulatory bodies to streamline distribution channels and eliminate barriers to availability. Global variations in opioid accessibility highlight the need for concerted efforts to address disparities. In some regions, regulatory frameworks may impede accessibility due to concerns about opioid misuse. Advocacy for balanced regulations that prioritize patient access while mitigating potential risks contributes to creating an environment conducive to the appropriate use of morphine. As awareness spreads and accessibility improves, the Global Morphine Drugs Market is poised to meet the increasing demand for effective pain management solutions. Striking a balance between responsible prescribing, patient education, and regulatory considerations ensures that morphine remains a valuable and accessible asset in the global healthcare landscape.

Key Market Challenges

Side Effects and Tolerance

Side effects and tolerance present significant challenges in the Global Morphine Drugs Market, influencing the effective management of pain while navigating potential drawbacks. Morphine, as an opioid analgesic, is known for its potent pain-relieving properties, but its use can be associated with a range of side effects. Common side effects of morphine include sedation, constipation, nausea, and respiratory depression. Balancing the need for adequate pain relief with these adverse effects requires careful consideration by healthcare professionals. Addressing and mitigating side effects become imperative to enhance patient comfort and adherence to prescribed regimens. Tolerance, a phenomenon where the body adapts to a drug, can occur with prolonged morphine use. As tolerance develops, patients may require higher doses to achieve the same level of pain relief. Managing tolerance poses a challenge as it involves careful monitoring, dose adjustments, and potentially exploring alternative pain management strategies. Respiratory depression, a serious side effect of opioids like morphine, underscores the need for vigilant monitoring, particularly in patients with respiratory conditions. Striking a balance between providing effective pain relief and minimizing the risk of respiratory depression is a constant challenge for healthcare professionals. Efforts to address these challenges include the development of extended-release formulations that aim to provide sustained pain relief with reduced frequency of dosing, potentially minimizing certain side effects. Research focuses on the optimization of drug delivery methods and formulations to improve the therapeutic profile of morphine. Patient education plays a crucial role in managing side effects and tolerance.

Abuse-Deterrent Formulations

Abuse-deterrent formulations represent a critical development in the Global Morphine Drugs Market, aiming to mitigate the risk of opioid misuse while ensuring access to effective pain management. Morphine, as an opioid analgesic, has faced concerns related to its potential for abuse, leading pharmaceutical companies to innovate and create formulations that deter misuse. Abuse-deterrent formulations incorporate technologies that make it more challenging for individuals to tamper with the drug for recreational purposes. These technologies aim to prevent crushing, chewing, or dissolving the medication, which are common methods used to extract the active ingredient for illicit use. The introduction of abuse-deterrent formulations aligns with broader efforts to address the opioid epidemic and enhance patient safety. These formulations not only safeguard against potential abuse but also contribute to minimizing the societal impact of opioid-related issues, including addiction and overdose. Common strategies employed in abuse-deterrent formulations include the use of physical barriers, aversive agents, or combinations thereof. Physical barriers make it difficult to alter the drug's form, while aversive agents, such as bitter substances, deter intentional misuse by rendering the drug unappealing. Despite the progress in abuse-deterrent technologies, it is essential to recognize that these formulations cannot eliminate the risk of opioid misuse entirely. They serve as one component of a multifaceted approach to address opioid-related challenges.

Key Market Trends

Increasing Focus on Personalized Medicine

The Global Morphine Drugs Market is witnessing a notable trend towards the increasing focus on personalized medicine, a paradigm that tailors medical treatment to individual patient characteristics. This trend is particularly relevant in the context of prescribing morphine, a powerful opioid analgesic, where individual variations in drug metabolism and response can significantly impact treatment outcomes. Personalized medicine in the context of morphine involves a comprehensive understanding of genetic factors influencing drug metabolism. Genetic variations in enzymes responsible for metabolizing morphine, such as cytochrome P450 enzymes, can lead to differences in how individuals process the drug. As a result, some patients may be more sensitive to morphine, experiencing enhanced pain relief, while others may metabolize it more rapidly, requiring adjustments in dosage to achieve the desired effect. Advancements in pharmacogenomics, the study of how genetic variations impact drug response, play a crucial role in tailoring morphine prescriptions. Genetic testing can help identify patients who may be at risk of adverse effects or those who may require higher or lower doses based on their genetic profile. This individualized approach aims to optimize pain management while minimizing the risk of side effects and improving overall patient safety and satisfaction. The integration of personalized medicine into the Global Morphine Drugs Market aligns with broader efforts in healthcare to move away from a one-size-fits-all approach and towards precision medicine. Healthcare providers are increasingly incorporating genetic information into treatment decisions, allowing for more informed and customized prescribing practices. As personalized medicine continues to gain traction, stakeholders in the Global Morphine Drugs Market are likely to witness increased collaboration between healthcare professionals, geneticists, and pharmaceutical companies. This collaborative effort aims to enhance the therapeutic benefits of morphine while addressing the inherent variability in individual patient responses, ultimately contributing to more effective and personalized pain management strategies.

Advancements in Drug Delivery Systems

Advancements in drug delivery systems are playing a pivotal role in shaping the landscape of the Global Morphine Drugs Market. These innovations are focused on enhancing the effectiveness, safety, and convenience of administering morphine, a potent opioid analgesic widely used for pain management. The evolution of drug delivery systems is driven by the imperative to optimize therapeutic outcomes while mitigating potential side effects associated with morphine use. One notable trend is the development of sustained-release formulations that offer prolonged and controlled release of morphine over an extended period. These formulations aim to provide consistent pain relief, reducing the need for frequent dosing and minimizing fluctuations in drug concentration. This not only enhances patient convenience but also contributes to improved adherence to prescribed regimens. Transdermal patches represent another significant advancement in drug delivery for morphine. These patches deliver the drug through the skin, providing a non-invasive and continuous release of morphine over an extended duration. This approach offers a valuable alternative for patients who may have difficulty with oral administration or who require a more controlled and long-lasting pain management solution. Implantable drug delivery systems are also emerging as a cutting-edge solution. These devices can be implanted subcutaneously to deliver controlled doses of morphine directly to the target site. Implantable systems offer the advantage of precise drug delivery, reducing the risk of systemic side effects and enhancing the overall efficacy of morphine therapy. Nanotechnology is increasingly being explored in the development of drug delivery systems for morphine. Nanocarriers can improve the bioavailability of morphine, enhance its solubility, and provide targeted delivery to specific tissues. This approach holds promise in optimizing the pharmacokinetics of morphine and reducing the required dosage, potentially minimizing side effects. As the Global Morphine Drugs Market continues to evolve, these advancements in drug delivery systems underscore the commitment to refining the therapeutic profile of morphine. Collaborative efforts between pharmaceutical companies, research institutions, and healthcare professionals are essential to furthering these innovations, ensuring that patients receive effective pain management with enhanced safety and convenience.

Segmental Insights

Application Insights

Based on Application, pain relief segment dominated the Global Morphine Drugs Market in 2023. This is ascribed due to to the widespread prevalence of chronic pain conditions, increasing surgical procedures, and rising awareness about effective pain management. Morphine, a potent analgesic, is a cornerstone in treating moderate to severe pain, making it a key choice for healthcare professionals. The growing aging population and rising instances of cancer contribute to the high demand for pain relief medications, solidifying the dominance of the pain relief segment in the global morphine drugs market.

Product Insights

Based on product, immediate release/short acting opioids segment dominated the Global Morphine Drugs Market in 2023. This is ascribed due to its quick onset of action, providing rapid pain relief. This characteristic makes it a preferred choice for managing acute and breakthrough pain, enhancing patient comfort. Physicians often prescribe short-acting opioids for postoperative pain, trauma, or cancer-related episodes. The flexibility in dosing and the ability to tailor treatment to individual patient needs contribute to the widespread adoption of immediate-release opioids, solidifying their dominance in the global morphine drugs market for addressing time-sensitive pain management requirements.

Regional Insights

North America dominated in the global Morphine Drugs market is attributed to several key factors. The region boasts advanced healthcare infrastructure and a well-established pharmaceutical industry. A high prevalence of pain-related conditions and a growing aging population contribute to the increased demand for morphine-based medications. Stringent regulatory standards ensure the safety and efficacy of morphine drugs, fostering trust in the market. The presence of major pharmaceutical players, substantial research and development investments, and a higher healthcare expenditure collectively propel North America to the forefront. These factors, combined with a widespread awareness of pain management, position the region as a leader in the global Morphine Drugs market..

Key Market Players

  • Hikma Pharmaceuticals plc
  • Pfizer Inc.
  • AbbVie Inc.
  • Sanofi S.A
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Endo, Inc.
  • Verve Health Care Ltd.
  • Mallinckrodt Pharmaceuticals

Report Scope:

In this report, the Global Morphine Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Morphine Drugs Market, By Product:

  • Immediate Release/ Short Acting Opioids
  • Extended Release/Long-Acting Opioids

Morphine Drugs Market, By Application:

  • Pain Relief
  • Anesthesia
  • Cough Suppression
  • Diarrhoea Suppression
  • De-addiction

Morphine Drugs Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Bioprocessing Probes and Sensors Market.

Available Customizations:

Global Morphine Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Morphine Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Immediate Release/ Short Acting Opioids, Extended Release/Long-Acting Opioids)
    • 5.2.2. By Application (Pain Relief, Anaesthesia, Cough Suppression, Diarrhoea Suppression, De-addiction)
    • 5.2.3. By Company (2023)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Morphine Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Morphine Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Application
    • 6.3.2. Mexico Morphine Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Application
    • 6.3.3. Canada Morphine Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Application

7. Europe Morphine Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Morphine Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Application
    • 7.3.2. Germany Morphine Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Morphine Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Morphine Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Morphine Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Application

8. Asia-Pacific Morphine Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Morphine Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Application
    • 8.3.2. India Morphine Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Application
    • 8.3.3. South Korea Morphine Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Application
    • 8.3.4. Japan Morphine Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Morphine Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Application

9. South America Morphine Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Morphine Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Application
    • 9.3.2. Argentina Morphine Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Application
    • 9.3.3. Colombia Morphine Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Application

10. Middle East and Africa Morphine Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Morphine Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Application
    • 10.3.2. Saudi Arabia Morphine Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Application
    • 10.3.3. UAE Morphine Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Application
    • 10.3.4. Egypt Morphine Drugs Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Product
        • 10.3.4.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porters Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Hikma Pharmaceuticals plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Pfizer Inc.
  • 14.3. AbbVie Inc.
  • 14.4. Sanofi S.A
  • 14.5. Viatris Inc.
  • 14.6. Sun Pharmaceutical Industries Ltd.
  • 14.7. Teva Pharmaceutical Industries Ltd.
  • 14.8. Endo, Inc.
  • 14.9. Verve Health Care Ltd.
  • 14.10. Mallinckrodt Pharmaceuticals

15. Strategic Recommendations

16. About Us & Disclaimer